Yahoo Finance

DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence

San Francisco, California--(Newsfile Corp. - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of ...
Yahoo Finance

DIMERx Awarded Up to $15M by NIDA Under NIH HEAL Initiative® to Advance DMX-101 as a Non-Addictive Oral Therapy for Chronic Pain

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage biopharmaceutical company entering growth phase, today announced it has been awarded a UG3/UH3 cooperative agreement ...
PharmiWeb

DIMERx to Present Data Showcasing Non-Addictive Opioid Dimer DMX-101 for Chronic Pain at PAINWeek 2023

SAN FRANCISCO--(BUSINESS WIRE)--#DIMERx--DIMERx, Inc., a mid-stage biopharmaceutical company, today announced that it will present data at PAINWeek 2023, the 17 th Annual National Conference on Pain ...
Mena FN

Dimerx Awarded Up To $15M By NIDA Under NIH HEAL Initiative® To Advance DMX-101 As A Non-Addictive Oral Therapy For Chronic Pain

(MENAFN- GlobeNewsWire - Nasdaq) The Award Highlights the Promise of Exclusively Targeting Peripheral Opioid Receptors to Treat Chronic Pain Without the Risk of Addiction and Dependence SAN FRANCISCO, ...
Finanznachrichten

DIMERx INC.: DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence

Key Regulatory Benchmark Met, Differentiating DMX-101 from Traditional Opioid Analgesics Late-Breaking Results to be Presented at CPDD 2026 Annual Meeting San Francisco, California--(Newsfile Corp. - ...